MedPlus Health Services shares dropped nearly 18% on Wednesday following a 21.7% decline in June quarter net profit. While total sales grew by 21.8%, rising employee costs and slower private label growth hurt profitability. Investors are now focused on how the pharmacy chain will manage its rising operational expenses and margin pressure in the coming quarters.
Detailed Coverage
MedPlus Health Services Ltd. faced a sharp market reaction on Wednesday, with its stock price sliding 17.65% during trading. The decline followed the company’s first-quarter financial results for the 2027 fiscal year, which revealed a mismatch between sales growth and profit generation. While the company reported total sales of ₹1,879.60 crore, a healthy 21.84% increase from the same period last year, the bottom line did not follow the same trend.
Net profit for the quarter dropped to ₹33.18 crore, down 21.67% from the ₹42.36 crore reported in the same quarter of the previous year. This indicates that despite the company selling more goods, it is struggling to convert that revenue into actual profit. The primary reason behind this profit erosion lies in rising costs and a change in the company's product mix.
Pressure on Profit Margins and Rising Overheads
One of the main areas affecting the company is the performance of its private label products. These products typically carry better profit margins than branded medicines. However, growth in this segment slowed significantly to just 2% year-on-year, failing to provide the expected boost to the company’s overall margins. At the same time, the company reported a 30% surge in pharmacy salaries, which is a major part of its overhead expenses. These combined factors resulted in a 163-basis-point drop in gross margins, marking the slowest gross profit growth for the company in four years.
Operating earnings, often referred to as EBITDA, fell 11% compared to the previous year and reportedly missed market expectations by a wide margin. These figures highlight the challenge of balancing rapid store expansion with the need to keep operating costs under control.
Long-Term Stock Performance
MedPlus has struggled significantly in the stock market compared to broader indices. Over the past month, the stock has declined by more than 19%. This underperformance is even more visible over a three-year period, where the stock has lost nearly 28%, while the Nifty Total Market index has seen gains of over 38%. This long-term trend suggests that shareholders have been facing consistent pressure, which the recent quarterly results have further intensified.
The most important factor for investors to track moving forward will be the company’s ability to control rising salary costs and revive growth in its higher-margin private label segment. Any future update on these specific operational costs or improvements in store-level efficiency will be critical to understanding if the company can return to improved profitability in the coming quarters.